摘要
Abstract
Objective To study the effect of rosuvastatin on plasma level of interleukin-18 (IL-18), high sensitivity C-reactive protein (hs-CRP), fasting blood glucose (FBG) and fasting insulin (FINS), as well as insulin resistance (IR) in patients with metabolic syndrome (MS). Methods Forty patients with MS were equally randomized to two groups: group A and group B. Patients in both groups were given antihypertensive therapy, at the same time, rosuvastatin was given to those in Group A with a dose of 10 mg, once a day. Plasma levels of low-density lipoprotein cholesterol, high-density lipoprotein cholesterol hs-CRP, IL-18, FBG and FINS were detected after six weeks of medication. IR was calculated. All examined items before and after six weeks treatment was analyzed. Results In comparison between before and after therapy, there were significant differences among all items in group A (t=4.20-21.19,P＜0.05); in group B, only differences between hs-CRP and FBG were significant (t=5.53,9.02;P＜0.05). The differences between two groups in the differentials of detected items before and after treatment were significant (t=17. 28,t'=4.90-20.85;P＜0.05). Conclusion Rosuvastatin can lower plasma level of hs-CRP and IL-18, as well as improve IR.关键词
瑞舒伐他汀/代谢综合征/C反应蛋白/白细胞介素18/胰岛素抵抗Key words
rosuvastatin/ metabolic syndrome/ C-reactive protein/ interleukin-18/ insulin resistance分类
医药卫生
